|
2025
|
P/S
|
Pharmaceutical preparations for diagnostic purposes, treatment and prevention of endometriosis, u... |
|
|
Invention
|
Substituted sulfonamide compound. The present invention addresses the problem of providing a nove... |
|
|
Invention
|
Substituted sulfonamide macrocyclic compound. The present invention addresses the problem of prov... |
|
2024
|
Invention
|
N-substituted cyclic amide compound. The present invention addresses the problem of providing a n... |
|
|
Invention
|
Nitrogen-containing condensed ring compound. The present invention addresses the problem of provi... |
|
|
Invention
|
Therapeutic agent for neurodegenerative disorder. The present invention addresses the problem of ... |
|
|
Invention
|
Method for producing compound encoded by oligonucleotide, and application thereof. The purpose of... |
|
|
Invention
|
Gonadotropin-releasing hormone antagonist dosing regimens for the treatment of endometriosis.
Th... |
|
2023
|
Invention
|
Biaryl compound. The present invention addresses the problem of providing a novel compound that h... |
|
|
Invention
|
Cyclopentane compound. The present invention addresses the problem of providing a novel compound ... |
|
|
Invention
|
Gonadotropin-releasing hormone antagonist dosing regimens for treating uterine fibroids and reduc... |
|
|
Invention
|
3,4-dihydroquinolin-2(1h)-one compound. The present invention addresses the problem of providing ... |
|
|
Invention
|
Oral solid preparation.
An object of the present invention is to provide an oral solid preparati... |
|
|
Invention
|
Oral solid preparation. The present invention addresses the problem of providing an oral solid pr... |
|
2021
|
Invention
|
Method for producing octahydrothienoquinoline compound, and production intermediate of same. 11 r... |
|
|
Invention
|
Succinate salts of octahydrothienoquinoline compound and crystals thereof.
An object of the pres... |
|
|
Invention
|
Succinate of octahydrothienoquinoline compound, and crystals thereof. [Problem] The present inven... |
|
|
Invention
|
Crystal of a hypoxanthine compound.
As a drug substance, a crystal having good physical properti... |
|
|
Invention
|
Crystal of imidazopyridinone compound or salt thereof.
As a drug substance, a crystal having goo... |
|
|
Invention
|
Crystal of imidazopyridinone compound or salt thereof. A crystal having excellent physical proper... |
|
|
Invention
|
Crystal of hypoxanthine compound. Preferred active pharmaceutical ingredients are crystals having... |
|
2020
|
P/S
|
Pharmaceutical preparations; Pharmaceutical preparations for diagnostic purposes, treatment and p... |
|
|
P/S
|
Pharmaceutical preparations, namely, pharmaceutical preparations for diagnostic purposes, treatme... |
|
|
P/S
|
Pharmaceutical preparations for treatment and prevention of endometriosis, uterine fibroids and o... |
|
|
P/S
|
Pharmaceutical preparations; pharmaceutical preparations for
diagnostic purposes, treatment and ... |
|
|
Invention
|
Gnrh antagonists for the treatment of estrogen-dependent disorders.
The present disclosure provi... |
|
|
Invention
|
Compositions and methods for treating metabolic disease. The invention described herein relates t... |
|
|
Invention
|
Chimeric antigen receptor-expressing cells targeting alk. A problem addressed by the present inve... |
|
|
Invention
|
Usage and dosage of therapeutic agents for endometriosis. An object of the present invention is t... |
|
|
Invention
|
Salt of fused heterocyclic derivative and crystal thereof.
The present invention provides 3-[2-f... |
|
2019
|
Invention
|
Compositions and methods for the treatment of estrogen-dependent disorders.
The present disclosu... |
|
|
Invention
|
Compositions and methods for the treatment of adenomyosis and rectovaginal endometriosis. The pre... |
|
|
Invention
|
High-efficiency method for producing genetically modified cells. The purpose of the present inven... |
|
|
Invention
|
Hypoxanthine compounds. The present invention relates to hypoxanthine compound or a pharmaceutica... |
|
|
Invention
|
Hypoxanthine compound. The present invention addresses the problem of providing a novel compound ... |
|
|
Invention
|
Imidazopyridinone compound. The present invention aims to provide a novel compound which has prol... |
|
|
Invention
|
Imidazopyridinone compound. The present invention addresses the problem of providing a novel comp... |
|
|
Invention
|
Sucroferric oxyhydroxide-containing granules and pharmaceutical composition. An object of the pre... |
|
|
Invention
|
Sucroferric oxyhydroxide-containing granules and pharmaceutical composition. [Problem] The presen... |
|
|
Invention
|
Method for treating post-prandial hypoglycemia. Disclosed herein are methods, sodium-dependent gl... |
|
|
Invention
|
Genetically modified cell and producing method therefor. Provided is a production of a cell expre... |
|
2018
|
Invention
|
Therapeutic agent for nocturnal pollakiuria. [Problem] To provide a novel therapeutic agent for n... |
|
|
Invention
|
Pyrrolidine compound. The present invention addresses the problem of providing a novel compound w... |
|
|
Invention
|
Condensed heterocyclic compound. The present invention addresses the problem of providing a novel... |
|
|
Invention
|
Fc fusion high affinity ige receptor alpha-chain.
Provided is an Fc fusion high affinity IgE rec... |
|
|
Invention
|
Salt of fused heterocyclic derivative and crystal thereof. The present invention provides 3-[2-fl... |
|
|
Invention
|
Gonadotropin-releasing hormone antagonist dosing regimens for the treatment of endometriosis. The... |
|
2017
|
Invention
|
Thiazole derivative or pharmacologically acceptable salt of same. The present invention addresses... |
|
|
Invention
|
Pyrrolidine derivative. 7 is alkyl or the like. The compounds of the present invention or a pharm... |
|
2016
|
Invention
|
Nk1 receptor antagonist. 1 receptor antagonist activity, and thus is useful for the prevention or... |
|
|
Invention
|
Pyrazole derivative or pharmaceutically acceptable salt thereof. The present invention is to prov... |
|
2015
|
Invention
|
Administration regimen for therapeutic agents for ataxia in spinocerebellar degeneration.
The pr... |
|
2010
|
P/S
|
Pharmaceutical products and preparations for treating
urinary tract disorders. |
|
2008
|
P/S
|
Pharmaceutical products and preparations for treating
urinary tract disorders, with the exceptio... |
|
|
P/S
|
Pharmaceutical products and preparations for treating urinary tract disorders. |
|
2006
|
P/S
|
Pharmaceutical products and preparations for treating urinary tract disorders, with the exceptio... |
|
|
P/S
|
Pharmaceutical products and preparations for treating urinary tract disorders, for sale under pre... |
|
2005
|
P/S
|
Pharmaceuticals; chemicals for medical use. |
